AXTALIS
Ottergemsesteenweg Zuid 808/b300
9000 Gent
BE
AXTALIS
Foundation date
23/03/2020
Sector
#Professional Services and ConsultingSubsector
- #Professional Services - Drug development consulting
- #Professional Services - Market access
- #Professional Services - Market research
- #Professional Services - Reimbursement and pricing
AxTalis is a consulting company that focuses on market access, regulatory affairs and medical affairs to support strategies and early launch implementation for academia, pharmaceutical/Biotech and device companies. Our vision is to broaden the perspectives of patients to access drugs in a sustainable manner by collaborating closely with physicians, researchers, companies, payers and patients.
Market Access services include strategy development including EU/US Landscaping & pricing, GVD development, reimbursement files, Health economic modeling and outcome research. Flexible staffing allows us to provide temporary FTEs to companies on a time or project basis.
Services for Medical Affairs include medical writing, support for training development and implementation, stakeholder interaction & advisory boards, project development and implementation (early access, data generation/RWE, speaker programs, patient support programs). The creation and production of medical and promotional materials are supported by our ‘RIP’ activity and print service.
Our Regulatory Affairs services include healthcare policy and all aspects related to obtaining and maintaining registration of therapeutic solutions in the EU and US. We also have a dedicated team that supports companies with pharmacovigilance and medical information.
Upcoming events
All events-
1012 '24
Next-Generation Synthetic Biology
Event by: VIB -
0312 '24
BioFIT 2024
Event by: Eurasanté -
0204 '25
The Franco-Belgian Agrifood Summit
Event by: CCI France - Belgique
Latest news
More news-
Bio Base Europe Pilot Plant successfully commissions a 75,000 L fermenter, demonstrating Vivici’s Vivitein™ BLG technology in industrial-scale precision fermentation
10 hours ago
Read more
-
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
1 day ago
Read more
-
ExeVir Announces Michael Garrett as New Chief Executive Officer
Tuesday November 19th 2024
Read more
Jobs
More jobs-
-
-
20/11/24
Antwerp
Postdoc position in the Laboratory for Gut-Immune-Brain Axis Research
Permanent
VIB
More info?
Ellen Telleir
Communication Coordinator